NCT05444478View on ClinicalTrials.gov

Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma

NARecruitingINTERVENTIONAL
Enrollment

274

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

July 1, 2025

Study Completion Date

July 1, 2027

Conditions
Hepatocellular CarcinomaMicrowave AblationLiver CancerLenvatinibRecurrent Tumor
Interventions
PROCEDURE

Microwave ablation

only microwave ablation for tumor

DRUG

Lenvatinib

lenvatinib (80 mg for body no more than 60kg，120 mg for body weight \>60 kg)

Trial Locations (1)

410011

RECRUITING

Hunan Provincial People's Hospital, Changsha

All Listed Sponsors
lead

Sun Yat-sen University

OTHER